Download PDF
Thromb Haemost 2011; 106(03): 416-422
DOI: 10.1160/TH11-03-0179
Blood Coagulation, Fibrinolysis and Cellular Haemostasis
Schattauer GmbH

Association of vitronectin and plasminogen activator inhibitor-1 levels with the risk of metabolic syndrome and type 2 diabetes mellitus

Results from the D.E.S.I.R. prospective cohort
Marie-Christine Alessi
1   U626, Inserm, Marseille, France
2   Université de la Méditerranée, Marseille, France
,
Viviane Nicaud
3   Inserm UMR_S 937, Université Pierre et Marie Curie (UPMC, Paris 6), Paris, France
,
Ilse Scroyen
1   U626, Inserm, Marseille, France
2   Université de la Méditerranée, Marseille, France
,
Celine Lange
4   Inserm, CESP Centre for research in Epidemiology and Population Health, U1018, Epidemiology of diabetes, obesity and chronic kidney disease over the lifecourse, Villejuif, France
5   Université Paris Sud 11, UMRS 1018, Villejuif, France
,
Noemie Saut
1   U626, Inserm, Marseille, France
2   Université de la Méditerranée, Marseille, France
,
Frederic Fumeron
6   U695, Inserm, Xavier Bichat Medical School, Paris, France
7   Université Paris Diderot – Paris 7, Paris, France
,
Michel Marre
6   U695, Inserm, Xavier Bichat Medical School, Paris, France
7   Université Paris Diderot – Paris 7, Paris, France
,
Olivier Lantieri
8   Regional Institute for Health, Tours, France
,
Benedicte Fontaine-Bisson
3   Inserm UMR_S 937, Université Pierre et Marie Curie (UPMC, Paris 6), Paris, France
9   Faculté des Sciences de la Santé, Université d'Ottawa, Ottawa, Ontario, Canada
,
Iréne Juhan-Vague
1   U626, Inserm, Marseille, France
2   Université de la Méditerranée, Marseille, France
,
Beverley Balkau
4   Inserm, CESP Centre for research in Epidemiology and Population Health, U1018, Epidemiology of diabetes, obesity and chronic kidney disease over the lifecourse, Villejuif, France
5   Université Paris Sud 11, UMRS 1018, Villejuif, France
,
David-Alexandre Tregouet
3   Inserm UMR_S 937, Université Pierre et Marie Curie (UPMC, Paris 6), Paris, France
,
Pierre-Emmanuel Morange
1   U626, Inserm, Marseille, France
2   Université de la Méditerranée, Marseille, France
,
D.E.S.I.R. Study Group › Author Affiliations Financial support: This work was supported in part by ANR grants ANR-07-PHYSIO-019–01 Obepi project and by the Fondation pour la recherché Médicale DEQ20071210508 (to MCA). The D.E.S.I.R. study has been supported by INSERM contracts with CNAMTS, Lilly, Novartis Pharma and Sanofi-Aventis; by INSERM (Réseaux en Santé Publique, Interactions entre les déterminants de la santé), Cohortes Santé TGIR, the Association Diabète Risque Vasculaire, the Fédération Française de Cardiologie, La Fondation de France, ALFEDIAM, ONIVINS, Ardix Medical, Bayer Diagnostics, Becton Dickinson, Cardionics, Merck Santé, Novo Nordisk, Pierre Fabre, Roche, Topcon.
Further Information

Publication History

Received: 15 March 2011

Accepted after major revision: 26 May 2011

Publication Date:
24 November 2017 (online)

Also available at
    Permissions and Reprints

Summary

It was the objective of this study to investigate the relation between vitronectin and plasminogen activator inhibitor (PAI)-1 plasma levels with nine-year incidences of the metabolic syndrome (MetS) and of type 2 diabetes mellitus (T2DM). Baseline plasma concentrations of vitronectin and PAI-1 were measured in 627 healthy participants from the prospective D.E.S.I.R. cohort who subsequently developed MetS (n=487) and T2DM (n=182) over a nine-year follow-up (42 presented both) and who were matched with two healthy control subjects each by use of a nested case-control design. Parameters composing the MetS explained about 20% of plasma vitronectin levels. An increase of one standard deviation of vitronectin was associated with increased risks of both the MetS (odds ratio [OR] = 1.21 [1.07 – 1.37], p = 0.003) and T2DM (OR = 1.24 [1.01 – 1.53], p = 0.045). Corresponding ORs for PAI-1 levels were 1.46 [1.27 – 1.68] (p < 10−4) and 1.40 [1.14 – 1.72] (p = 0.0012). However, the effects of vitronectin and PAI-1 levels on outcomes were not independent. The vitronectin–MetS association was restricted to individuals with low to modest PAI-1 levels (OR = 1.33 [1.14 – 1.54], p = 0.0003) while no association was observed in individuals with high PAI-1 levels (OR = 0.87 [0.68 – 1.10], p = 0.24), the test for interaction being highly significant (p = 0.0009). In conclusion, baseline plasma vitronectin is a marker of incident MetS at nine years. Its predictive ability for MetS and T2DM should not be assessed independently of PAI-1 levels.

Keywords

PAI-1 - vitronectin - metabolic syndrome - diabetes

 

  • References

  • 1 Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005; 365: 1415-1428.
    CrossrefPubMedGoogle Scholar
  • 2 Malik S, Wong ND, Franklin SS. et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 2004; 110: 1245-1250.
    CrossrefPubMedGoogle Scholar
  • 3 Hu G, Qiao Q, Tuomilehto J. et al. DECODE Study Group. Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. Arch Intern Med 2004; 164: 1066-1076.
    CrossrefPubMedGoogle Scholar
  • 4 Sattar N, Wannamethee SG, Forouhi NG. Novel biochemical risk factors for type 2 diabetes: pathogenic insights or prediction possibilities?. Diabetologia 2008; 51: 926-940.
    CrossrefPubMedGoogle Scholar
  • 5 Lijnen HR. Pleiotropic functions of plasminogen activator inhibitor-1. J Thromb Haemost 2005; 3: 35-45.
    CrossrefPubMedGoogle Scholar
  • 6 Mertens I, Verrijken A, Michiels JJ. et al. Among inflammation and coagulation markers, PAI-1 is a true component of the metabolic syndrome. Int J Obes (Lond) 2006; 30: 1308-1314.
    CrossrefPubMedGoogle Scholar
  • 7 Dimova EY, Kietzmann T. Metabolic, hormonal and environmental regulation of plasminogen activator inhibitor-1 (PAI-1) expression: lessons from the liver. Thromb Haemost 2008; 100: 992-1006.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 8 Alessi MC, Juhan-Vague I. Metabolic syndrome, haemostasis and thrombosis. Thromb Haemost 2008; 99: 995-1000.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 9 Cigolini M, Targher G, Bergamo Andreis IA. et al. Visceral fat accumulation and its relation to plasma hemostatic factors in healthy men. Arterioscler Thromb Vasc Biol 1996; 16: 368-374.
    CrossrefPubMedGoogle Scholar
  • 10 Meigs JB, Mittleman MA, Nathan DM. et al. Hyperinsulinemia, hyperglycemia, and impaired hemostasis: the Framingham Offspring Study. J Am Med Assoc 2000; 283: 221-228.
    CrossrefPubMedGoogle Scholar
  • 11 Gray RP, Panahloo A, Mohamed-Ali V. et al. Proinsulin-like molecules and plasminogen activator inhibitor type 1 (PAI-1) activity in diabetic and non-diabetic subjects with and without myocardial infarction. Atherosclerosis 1997; 130: 171-178.
    CrossrefPubMedGoogle Scholar
  • 12 Alessi MC, Juhan-Vague I. PAI-1 and the metabolic syndrome: links, causes, and consequences. Arterioscler Thromb Vasc Biol 2006; 26: 2200-2207.
    CrossrefPubMedGoogle Scholar
  • 13 Ingelsson E, Pencina MJ, Tofler GH. et al. Multimarker approach to evaluate the incidence of the metabolic syndrome and longitudinal changes in metabolic risk factors: the Framingham Offspring Study. Circulation 2007; 116: 984-992.
    CrossrefPubMedGoogle Scholar
  • 14 Festa A, D’Agostino R, Jr Tracy RP. et al. Insulin Resistance Atherosclerosis Study. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type II diabetes: the insulin resistance atherosclerosis study. Diabetes 2002; 51: 1131-1137.
    CrossrefPubMedGoogle Scholar
  • 15 Festa A, Williams K, Tracy RP. et al. Progression of plasminogen activator in- hibitor-1 and fibrinogen levels in relation to incident type II diabetes. Circulation 2006; 113: 1753-1759.
    CrossrefPubMedGoogle Scholar
  • 16 Meigs JB, O’donnell CJ, Tofler GH. et al. Hemostatic markers of endothelial dysfunction and risk of incident type 2 diabetes: the Framingham Offspring Study. Diabetes 2006; 55: 530-537.
    CrossrefPubMedGoogle Scholar
  • 17 Ma L-J, Mao S-L, Taylor KL. et al. Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor 1. Diabetes 2004; 53: 336-346.
    CrossrefPubMedGoogle Scholar
  • 18 Liang X, Kanjanabuch T, Mao SL. et al. Plasminogen activator inhibitor-1 modulates adipocyte differentiation. Am J Physiol Endocrinol Metab 2006; 290: E103-E113.
    CrossrefPubMedGoogle Scholar
  • 19 Schäfer K, Fujisawa K, Konstantinides S. et al. Disruption of the plasminogen activator inhibitor 1 gene reduces the adiposity and improves the metabolic profile of genetically obese and diabetic ob/ob mice. FASEB J 2001; 15: 1840-1842.
    CrossrefPubMedGoogle Scholar
  • 20 Schvartz I, Seger D, Shaltiel S. Vitronectin. Int J Biochem Cell Biol. 1999; 31: 539-44.
    CrossrefPubMedGoogle Scholar
  • 21 Declerck PJ, De Mol M, Alessi MC. et al. Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma. Identification as a multimeric form of S protein (vitronectin). J Biol Chem 1988; 263: 15454-15461.
    PubMedGoogle Scholar
  • 22 Lebrun P, Baron V, Hauck CR. et al. Cell adhesion and focal adhesion kinase regulate insulin receptor substrate-1 expression. J Biol Chem 2000; 275: 38371-38377.
    CrossrefPubMedGoogle Scholar
  • 23 Dupont DM, Madsen JB, Kristensen T. et al. Biochemical properties of plasminogen activator inhibitor-1. Front Biosci 2009; 14: 1337-1361.
    PubMedGoogle Scholar
  • 24 López-Alemany R, Redondo JM, Nagamine Y. et al. Plasminogen activator inhibitor type-1 inhibits insulin signaling by competing with alphavbeta3 integrin for vitronectin binding. Eur J Biochem 2003; 270: 814-821.
    CrossrefPubMedGoogle Scholar
  • 25 Kaido T, Yebra M, Cirulli V. et al. Impact of defined matrix interactions on insulin production by cultured human beta-cells: effect on insulin content, secretion, and gene transcription. Diabetes 2006; 55: 2723-2729.
    CrossrefPubMedGoogle Scholar
  • 26 Balkau B, Eschwege E, Tichet J. et al. Proposed criteria for the diagnosis of diabetes: evidence from a French epidemiological study (D.E.S.I.R.). Diabetes Metab 1997; 23: 428-434.
    PubMedGoogle Scholar
  • 27 Grundy SM, Cleeman JI, Daniels SR. et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112: 2735-2752.
    CrossrefPubMedGoogle Scholar
  • 28 Vari IS, Balkau B, Kettaneh A. et al. Ferritin and transferrin are associated with metabolic syndrome abnormalities and their change over time in a general population: Data from an Epidemiological Study on the Insulin Resistance Syndrome (DESIR). Diabetes Care 2007; 30: 1795-1801.
    CrossrefPubMedGoogle Scholar
  • 29 Tregouet DA, Garelle V. A new JAVA interface implementation of THESIAS: testing haplotype effects in association studies. Bioinformatics 2007; 23: 1038-1039.
    CrossrefPubMedGoogle Scholar
  • 30 Ekmekci H, Sonmez H, Ekmekci OB. et al. Plasma vitronectin levels in patients with coronary atherosclerosis are increased and correlate with extent of disease. J Thromb Thrombolysis 2002; 14: 221-225.
    CrossrefPubMedGoogle Scholar
  • 31 Derer W, Barnathan ES, Safak E. et al. Vitronectin Concentrations Predict Risk in Patients Undergoing Coronary Stenting. Circ Cardiovasc Intervent 2009; 2: 14-19.
    CrossrefPubMedGoogle Scholar
  • 32 Tollefsen DM, Weigel CJ, Kabeer MH. The presence of methionine or threonine at position 381 in vitronectin is correlated with proteolytic cleavage at arginine 379. J Biol Chem 1990; 265: 9778-9781.
    PubMedGoogle Scholar
  • 33 Chain D, Korc-Grodzicki B, Kreizman T. et al. The phosphorylation of the two-chain form of vitronectin by proteinkinase A is heparin dependent. FEBS Lett 1990; 269: 221-225.
    CrossrefPubMedGoogle Scholar
  • 34 Chain D, Korc-Grodzicki B, Kreizman T. et al. Endogenous cleavage of the Arg-379-Ala-380 bond in vitronectin results in adistinct conformational change which ‘buries’ Ser-378, its site of phosphorylation by protein kinase A. Biochem J 1991; 274: 387-394.
    CrossrefPubMedGoogle Scholar
  • 35 Izumi M, Yamada KM, Hayashi M. Vitronectin exists in two structurally and functionally distinct forms in human plasma. Biochim Biophys Acta 1989; 990: 101-108.
    CrossrefPubMedGoogle Scholar
  • 36 Yoneda A, Ogawa H, Kojima K. et al. Characterization of the ligand binding activities of vitronectin: interaction of vitronectin with lipids and identification of the binding domains for various ligands using recombinant domains. Biochemistry 1998; 37: 6351-6360.
    CrossrefPubMedGoogle Scholar